20
November 2024
PureTech Health plc
PureTech Founded
Entity Seaport Therapeutics Adds Sandi Peterson to its Board of
Directors
Lead Independent Director at
Microsoft and former Group Worldwide Chair for Johnson &
Johnson brings extensive experience in life sciences innovation,
governance and operations
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, noted that
its Founded Entity, Seaport
Therapeutics, ("Seaport") a
biopharmaceutical company that is advancing novel neuropsychiatric
medicines with a proven strategy and team, today announced that Sandra (Sandi)
Peterson has been appointed to its Board of Directors. Ms. Peterson
is a prominent and seasoned business leader with extensive
experience driving innovation and operational excellence across
leading global life sciences and consumer organizations.
The full text of the announcement
from Seaport is as follows:
Seaport Therapeutics Adds
Sandi Peterson to its Board of Directors
Lead Independent Director at
Microsoft and former Group Worldwide Chair for Johnson &
Johnson brings extensive experience in life sciences innovation,
governance and operations
BOSTON, November 20, 2024 - Seaport
Therapeutics ("Seaport" or the
"Company"), a clinical-stage biopharmaceutical company that is
advancing novel neuropsychiatric medicines with a proven strategy
and team, today announced that Sandra (Sandi) Peterson has been
appointed to its Board of Directors. Ms. Peterson is a prominent
and seasoned business leader with extensive experience driving
innovation and operational excellence across leading global life
sciences and consumer organizations.
Ms. Peterson has held a series of
high-profile leadership roles over the course of her career.
Currently, she is an Operating Partner at Clayton, Dubilier &
Rice, (CD&R), a private investment firm, where she invests in
life sciences and consumer companies and oversees technology
initiatives to enhance performance of the firm's portfolio
companies. Prior to joining CD&R in 2019, Ms. Peterson was
Group Worldwide Chair for Johnson & Johnson (J&J), where
she led the company's consumer and medical devices businesses and
was responsible for global operating infrastructure, technology,
supply chain, quality and key strategic initiatives.
"Sandi has garnered a wealth of
experience over the course of her impressive career that will be a
tremendous asset to Seaport as we advance novel neuropsychiatric
medicines for patients and their families," said Daphne Zohar,
Founder and Chief Executive Officer of Seaport Therapeutics. "We
are fortunate to have excellent individuals on our Board of
Directors who each contribute unique expertise, and Sandi's proven
ability to drive innovation and scale global businesses will be
particularly meaningful as we accelerate development of our
pipeline."
Previously, Ms. Peterson served as
Chairman & CEO of Bayer CropScience AG, CEO of Bayer Medical
Care, and President of Bayer HealthCare AG's Diabetes Care
Division. She held executive positions at Medco Health Solutions
(formerly known as Merck-Medco), Nabisco, Whirlpool and McKinsey.
In addition to her Board position at Seaport, Ms. Peterson serves
on the Microsoft Board of Directors as the lead independent
director; Executive Chairwoman of Volastra Therapeutics; Board
Chair of the American Academy in Berlin and Executive Committee
Member of the Institute for Advanced Study.
"Seaport's innovative approach to
developing new medicines for neuropsychiatric conditions has the
potential to radically transform the treatment landscape for
patients, particularly for those suffering from depression and
anxiety," said Ms. Peterson. "I look forward to working with
Seaport's excellent leadership team and Board to drive forward our
commitment to improve patient outcomes through science and
innovation."
Ms. Peterson has appeared on
Fortune Magazine's list of
Most Powerful Women in Business numerous times and was featured on
the magazine's inaugural list of Leaders Who Are Changing
Healthcare. She received her B.A. from Cornell University and her
M.P.A. from Princeton University.
About Seaport Therapeutics
Seaport Therapeutics is a
clinical-stage biopharmaceutical company advancing the development
of novel neuropsychiatric medicines in areas of high unmet patient
needs. The Company has a proven strategy of advancing clinically
validated mechanisms previously held back by limitations that are
overcome with its proprietary Glyph technology platform. All
the therapeutic candidates in its pipeline of first and
best-in-class medicines are based on the Glyph platform, which is
uniquely designed to enable oral bioavailability, bypass first-pass
metabolism and reduce liver enzyme elevations or hepatotoxicity and
other side effects. Seaport is led by an experienced team that
invented and advanced important neuropsychiatric medicines and are
guided by an extensive network of renowned scientists, clinicians
and key opinion leaders. For more information, please
visit www.seaporttx.com.
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating diseases.
The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders that is being
advanced both internally and through its Founded Entities.
PureTech's R&D engine has resulted in the development of 29
therapeutics and therapeutic candidates, including three that have
been approved by the U.S. Food and Drug Administration. A number of
these programs are being advanced by PureTech or its Founded
Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit
www.puretechhealth.com
or connect with us on X (formerly Twitter)
@puretechh.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains
statements that are or may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation those related to Seaport's
development plans for its pipeline of therapeutics for the
treatment of depression, anxiety and other neuropsychiatric
disorders, potential benefits to patients, and Seaport's and our
future prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2023, filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US
Media
Justin Chen
+1-609-578-7230
jchen@tenbridgecommunications.com